Y Combinator General Partner Ankit Gupta has outlined two critical factors for bio-founders aiming to elevate their companies, emphasizing the strategic importance of data generation and predictable scaling laws. Gupta, a prominent figure with a deep background in machine learning and biotech, shared his insights in a recent social media post, offering a clear prompt for startups in the life sciences sector.
"this has often been my prompt to YC bio founders about how to up-level their companies: 1) is there a way you can generate a large amount of (ideally differentiated) multiplexed in-vivo data? 2) is there a predictable scaling law between your data and model performance? if yes to both: you're in business," Ankit Gupta stated in the tweet.
Gupta's advice underscores the growing convergence of biotechnology and artificial intelligence. His focus on "multiplexed in-vivo data" points to the necessity of collecting diverse, real-time biological information from living organisms, which can provide a more comprehensive understanding of complex biological systems than traditional in-vitro methods. This type of data is crucial for developing accurate and robust computational models in drug discovery and personalized medicine.
The second criterion, "a predictable scaling law between your data and model performance," highlights the need for a clear relationship where increasing the quantity and quality of data directly translates to improved model accuracy and predictive power. This concept, often seen in large language models, is becoming increasingly vital in biotech for efficiently training AI systems that can accelerate research and development. Ankit Gupta joined Y Combinator as a General Partner in September 2025, bringing his expertise from co-founding Reverie Labs, a biotech company acquired by Ginkgo Bioworks, which applied machine learning to drug discovery.
His move to Cambridge, Massachusetts, signifies Y Combinator's renewed focus on the East Coast's burgeoning biotech and AI ecosystem. Gupta's guidance reflects YC's strategy to back founders at the cutting edge of AI and life sciences, particularly those who can demonstrate a clear path from data acquisition to impactful model development. The ability to meet these two conditions, according to Gupta, positions a bio-startup for significant success in a competitive and rapidly evolving industry.
